Evonik Evonik

X

Find Drugs in Development News & Deals for Naproxen Sodium

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
37
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - EQ 500MG BASE
  • TABLET;ORAL - 220MG
  • TABLET, EXTENDED RELEASE;ORAL - EQ 375MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 500MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 750MG BASE
  • CAPSULE;ORAL - EQ 200MG BASE
  • TABLET;ORAL - 500MG;EQ 85MG BASE
  • TABLET;ORAL - 60MG;EQ 10MG BASE

Details:

Dr. Reddy’s OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal antiinflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains.


Lead Product(s): Naproxen Sodium

Therapeutic Area: Neurology Product Name: Naproxen Sodium-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2021

Details:

USFDA approved generic version of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.


Lead Product(s): Naproxen Sodium

Therapeutic Area: Neurology Product Name: Naproxen Sodium-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2022

Details:

The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.


Lead Product(s): Naproxen Sodium,Sumatriptan

Therapeutic Area: Neurology Product Name: Suvexx

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Orion Corporation

Deal Size: $0.6 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog.


Lead Product(s): Naproxen Sodium,Pseudoephedrine Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Pusen OK

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.


Lead Product(s): Naproxen Sodium,Sumatriptan

Therapeutic Area: Neurology Product Name: Suvexx

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Orion Corporation

Deal Size: Undisclosed Upfront Cash: $2.0 million

Deal Type: Partnership December 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY